Clinical Decision-Making About Neoadjuvant Nivolumab Plus Ipilimumab

被引：2
|
作者：
Gil-Sierra, Manuel David [1 ,2 ]
Sanchez-Hidalgo, Marina [1 ]
Alarcon de la Lastra-Romero, Catalina [1 ]
机构：
[1] Univ Seville, Fac Pharm, Dept Pharmacol, Calle Prof Garcia Gonzalez 2, Seville 41012, Spain
[2] Hosp Doctor Jose Molina Orosa, Dept Pharm, Arrecife, Spain
来源：
JAMA ONCOLOGY | 2021年 / 7卷 / 02期
关键词：
D O I：
10.1001/jamaoncol.2020.6989
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：309 / 309
页数：1
相关论文
共 50 条
  • [21] Nivolumab plus ipilimumab for advanced MPM
    Venkatesan, Priya
    LANCET RESPIRATORY MEDICINE, 2020, 8 (10): : E76 - E76
  • [22] Ipilimumab plus nivolumab for advanced melanoma
    Hassel, Jessica C.
    LANCET ONCOLOGY, 2016, 17 (11): : 1471 - 1472
  • [23] Adverse events with nivolumab plus ipilimumab
    Reactions Weekly, 2017, 1671 (1) : 8 - 8
  • [24] Nivolumab plus Ipilimumab in Advanced Melanoma
    Santhosh, Akhil
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (12): : 1245 - 1246
  • [25] Effect of a Video Decision Aid on Clinical Decision-Making About Cardiopulmonary Resuscitation
    You, John J.
    Swinton, Marilyn
    Mantle, Carol
    Jayaraman, Dev
    Heyland, Daren K.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2016, 52 (06) : E77 - E77
  • [26] Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial
    Schoenfeld, Jonathan D.
    Hanna, Glenn J.
    Jo, Vickie Y.
    Rawal, Bhupendra
    Chen, Yu-Hui
    Catalano, Paul S.
    Lako, Ana
    Ciantra, Zoe
    Weirather, Jason L.
    Criscitiello, Shana
    Luoma, Adrienne
    Chau, Nicole
    Lorch, Jochen
    Kass, Jason I.
    Annino, Donald
    Goguen, Laura
    Desai, Anupam
    Ross, Brendan
    Shah, Hina J.
    Jacene, Heather A.
    Margalit, Danielle N.
    Tishler, Roy B.
    Wucherpfennig, Kai W.
    Rodig, Scott J.
    Uppaluri, Ravindra
    Haddad, Robert I.
    JAMA ONCOLOGY, 2020, 6 (10) : 1563 - 1570
  • [27] Clinical outocomes of nivolumab plus ipilimumab in metastatic renal cell carinoma
    Kato, Taigo
    Fujita, Kazutoshi
    Nagahara, Akira
    Nakata, Wataru
    Matsuzaki, Kyousuke
    Hatano, Koji
    Kawashima, Atsunari
    Takada, Shingo
    Nishimura, Kensaku
    Tsujihata, Masao
    Takao, Tetsuya
    Nakai, Yasutomo
    Nakayama, Masashi
    Nishimura, Kazuo
    Uemura, Motohide
    Uemura, Hirotsugu
    Nonomura, Norio
    ANNALS OF ONCOLOGY, 2023, 34 : S1412 - S1412
  • [28] Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
    Cascone, T.
    William, W. N.
    Weissferdt, A.
    Leung, C. H.
    Federico, L.
    Haymaker, C.
    Bernatchez, C.
    Fossella, F. V.
    Mott, F. E.
    Papadimitrakopoulou, V. A.
    Byers, L.
    Lam, V. K.
    Godoy, M. C.
    Carter, B.
    Lee, J. J.
    Vaporciyan, A.
    Gibbons, D. L.
    Swisher, S. G.
    Heymach, J. V.
    Sepesi, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [29] Nivolumab plus ipilimumab: fewer AEs with lower dose ipilimumab
    Reactions Weekly, 2022, 1895 (1) : 7 - 7
  • [30] Breast conservation after neoadjuvant chemotherapy - A prognostic index for clinical decision-making
    Chen, AM
    Meric-Bernstam, F
    Hunt, KK
    Thames, HD
    Outlaw, ED
    Strom, EA
    McNeese, MD
    Kuerer, HM
    Ross, MI
    Singletary, SE
    Ames, FC
    Feig, BW
    Sahin, AA
    Perkins, GH
    Babiera, G
    Hortobagyi, GN
    Buchholz, TA
    CANCER, 2005, 103 (04) : 689 - 695
12345